Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2800 participants
OBSERVATIONAL
2024-04-01
2036-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lipoprotein(a) and Progression of Aortic Stenosis
NCT06648915
Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention
NCT01245855
Extended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome
NCT01223586
24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial
NCT06014060
Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)
NCT00242944
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Working General Population
Consenting hospital staff are recruited to this study. Blood test and questionnaires are taken at baseline. Prospective follow-up of cardiovascular events are undertaken.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Study team members can also be recruited because we are trying to find the prevalence of elevated Lp(a)
Exclusion Criteria
2. Pregnant women.
3. Prisoner
21 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changi General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Loh Wann Jia
Primary Investigator and Consultant Endocrinologist.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Loh Wann Jia
Role: PRINCIPAL_INVESTIGATOR
Singhealth Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trials & Research Unit
Singapore, Singapore, Singapore
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lim
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Loh WJ, Watts GF. Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle? Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):94-102. doi: 10.1097/MED.0000000000000789. Epub 2022 Dec 5.
Loh WJ, Chang X, Aw TC, Phua SK, Low AF, Chan MY, Watts GF, Heng CK. Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population. Atherosclerosis. 2022 May;349:160-165. doi: 10.1016/j.atherosclerosis.2021.11.018. Epub 2021 Nov 26.
Loh WJ, Chan DC, Mata P, Watts GF. Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Front Genet. 2022 Apr 27;13:905941. doi: 10.3389/fgene.2022.905941. eCollection 2022.
Nestel P, Loh WJ, Ward NC, Watts GF. New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. J Clin Endocrinol Metab. 2022 Nov 23;107(11):e4281-e4294. doi: 10.1210/clinem/dgac541.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgozoglu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIRB2023/2651
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.